2025-11-06 - Analysis Report
Okay, here's an analysis of Johnson & Johnson (JNJ) based on the information you provided, presented in English with a focus on key figures and concise analysis.

## Johnson & Johnson (JNJ) Stock Analysis

Johnson & Johnson is a global healthcare company that develops, manufactures, and sells a broad range of products in the healthcare field.

### 1. Performance vs. S&P 500 (VOO)

*   **JNJ Cumulative Return:** 42.93%
*   **VOO Cumulative Return:** 99.52%
*   **Absolute Performance Difference:** -61.5%
*   **Relative Performance Divergence:** 4.9

**Analysis:** JNJ has significantly underperformed the S&P 500 over the analyzed period. The relative divergence figure suggests that JNJ's current underperformance is near the lower end of its historical range compared to the S&P 500. It is still better performing about 4.9% then historical data.

**Alpha, Beta Analysis:**

| Year       | CAGR   | MDD   | Alpha  | Beta | Cap(B) |
|------------|--------|-------|--------|------|--------|
| 2015-2017  | 26.0%  | 66.8% | -2.0%  | -0.1 | 336.5  |
| 2016-2018  | 14.0%  | 10.7% | -1.0%  | 0.1  | 310.8  |
| 2017-2019  | 20.0%  | 71.5% | -2.0%  | 0.4  | 351.3  |
| 2018-2020  | 19.0%  | 79.2% | -4.0%  | 0.4  | 379.1  |
| 2019-2021  | 33.0%  | 79.2% | -14.0% | 0.5  | 412.0  |
| 2020-2022  | 8.0%   | 79.6% | 9.0%   | 0.4  | 425.5  |
| 2021-2023  | -19.0% | 79.6% | -20.0% | 0.3  | 377.5  |
| 2022-2024  | -32.0% | 79.6% | -53.0% | 0.3  | 348.3  |
| 2023-2025  | 14.0%  | 79.6% | -50.0% | 0.1  | 448.1  |

*   **CAGR:** Fluctuating CAGR indicates inconsistent growth patterns over the years.
*   **MDD:** High Maximum Drawdown (MDD) values suggest significant potential losses during downturns.
*   **Alpha:** Predominantly negative Alpha values imply underperformance compared to the benchmark.
*   **Beta:** Beta values between -0.1 and 0.5 suggest relatively low volatility compared to the market, with the stock generally moving less than the market.
*   **Cap:** Market Cap indicates the company's size, but it has fluctuated, reflecting market conditions and company performance.

### 2. Recent Stock Price Movement

*   **Current Price:** $186.035
*   **Last Market Data:** Price: $185.995, Previous Close: $186.86, Change: -$0.46
*   **5-day Moving Average:** 187.363
*   **20-day Moving Average:** 190.132
*   **60-day Moving Average:** 182.4693

**Analysis:** The stock price is currently below both the 5-day and 20-day moving averages, suggesting a short-term downtrend. However, it's above the 60-day moving average, indicating a potentially stronger longer-term trend. The slight decrease in the last market price indicates very little downward pressure.

### 3. Technical Indicators and Market Risk

*   **MRI:** 0.9 (High Investment Recommended)
*   **RSI:** 37.29
*   **PPO:** -0.59
*   **Hybrid Signal:** cash_0%_Buy 100% of cash (688 shares - Very Safe - MRI:0.90)
*   **Recent (20-day) Relative Divergence Change:** -12.4 (Decreasing)
*   **Expected Return:** -437.8%

**Analysis:**

*   The MRI suggests a "High Investment Recommended" level of risk, which seems to contradict some of the negative performance data.
*   The RSI of 37.29 indicates that the stock is nearing oversold conditions but is not quite there yet.
*   A negative PPO suggests a downward trend in price momentum.
*   The Hybrid Signal recommends buying JNJ.
*   The negative change in relative divergence indicates further underperformance compared to the benchmark.
*   The extremely negative expected return raises a red flag, suggesting significant potential underperformance over the long term.

### 4. Recent News & Significant Events

*   **Negative Headline:** "This Healthcare Stock Is Worst Performer in the S&P 500 Today" indicates recent negative market sentiment.
*   **Neutral/Mixed Headlines:** Other headlines mention Johnson & Johnson as a "trending stock" and discuss related industry events (Kimberly-Clark's acquisition), which could have indirect impacts.
*   **Disposable Medical Device Market Report:** The positive outlook for the disposable medical device market could be a long-term positive for JNJ.

### 4.2 Analyst Opinions

*   **Consensus:** "Buy" (Mean: 2.17)
*   **Target Price:** Average: $199.56, High: $225.00, Low: $155.00

**Analysis:** Analysts generally have a positive outlook on the stock, with a consensus "Buy" rating. The average target price suggests potential upside from the current price.

### 5. Recent Earnings Analysis

| 날짜         | EPS  | 매출       |
|--------------|------|------------|
| 2025-10-22   | 2.14 | 23.99 B$   |
| 2025-07-24   | 2.3  | 23.74 B$   |
| 2025-04-23   | 4.57 | 21.89 B$   |
| 2024-10-23   | 1.12 | 22.47 B$   |
| 2025-10-22   | 1.12 | 22.47 B$   |

**Analysis:** The EPS and revenue figures show some fluctuation. The most recent EPS is lower than the previous two quarters, while revenue has been relatively stable.

### 6. Financial Information

**Revenue and Profitability:**

| Quarter    | Revenue   | Profit Margin |
|------------|-----------|---------------|
| 2025-06-30 | $23.74B   | 67.87%        |
| 2025-03-31 | $21.89B   | 66.40%        |
| 2024-12-31 | $22.52B   | 68.35%        |
| 2024-09-30 | $22.47B   | 69.01%        |
| 2024-06-30 | $22.45B   | 69.40%        |

**Capital and Profitability:**

| Quarter    | Equity    | ROE     |
|------------|-----------|---------|
| 2025-06-30 | $78.47B   | 7.06%   |
| 2025-03-31 | $78.11B   | 14.08%  |
| 2024-12-31 | $71.49B   | 4.80%   |
| 2024-09-30 | $70.16B   | 3.84%   |
| 2024-06-30 | $71.54B   | 6.55%   |

**Analysis:** The profit margins have been relatively high and stable, indicating strong profitability. ROE has fluctuated, suggesting variations in the company's efficiency in generating profit from equity. Equity has generally increased.

### 7. Overall Assessment

Johnson & Johnson (JNJ) presents a mixed picture based on the provided data. While analysts have a generally positive outlook (Buy rating), the stock has significantly underperformed the S&P 500. Recent news headlines highlight negative performance, and technical indicators suggest some downward momentum. The extremely negative expected return is a major concern.

**Key Considerations:**

*   **Underperformance:** The substantial underperformance relative to the S&P 500 needs to be carefully investigated.
*   **Conflicting Signals:** The "High Investment Recommended" MRI score contrasts with the negative performance data.
*   **Analyst Optimism vs. Reality:** The discrepancy between analyst ratings and recent stock performance warrants further scrutiny.

**Recommendation:** A cautious approach is advised. Further research is needed to understand the reasons behind the underperformance and the validity of the conflicting signals before making any investment decisions.
